Healthcare / BiotechnologyTokyo
$322.00
-26.00 (-7.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $283.0M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.4B
P/E
585.5x
↑EV/EBITDA
5.6x
↓ROE
0.2%
↓Gross Margin
56.2%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.6%
FCF CAGR
-27.7%
FCF margin
7.6%
FCF / Net income
26.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.71B · net income $10.7M · FCF $283.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.71B | $3.71B | $4.36B | $4.51B | $4.27B |
| Net Income | $10.7M | $10.7M | $237.9M | $923.1M | $1.02B |
| EBITDA | $309.4M | $309.4M | $438.3M | $1.30B | $1.63B |
| EPS | — | — | 11.96 | 47.93 | 52.98 |
| Gross Margin | 56.2% | 56.2% | 55.5% | 70.6% | 71.7% |
| Operating Margin | 4.5% | 4.5% | 3.0% | 27.1% | 36.8% |
| Net Margin | 0.3% | 0.3% | 5.5% | 20.5% | 23.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.02 | — |
| Current Ratio | 13.95 | 13.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $283.0M | $283.0M | $52.0M | $487.7M | $748.4M |
| Returns | |||||
| ROE | 0.2% | 0.2% | 3.9% | 14.9% | 26.9% |
| Valuation | |||||
| P/E | 585.45 | 585.45 | 98.16 | 35.22 | 84.94 |
| EV/EBITDA | 5.58 | 5.58 | 43.61 | 21.34 | 51.15 |
| P/B | 1.06 | 1.06 | 3.87 | 5.24 | 22.84 |
| Growth & Yield | |||||
| Revenue Growth | -14.8% | -14.8% | -3.4% | 5.5% | — |
| EPS Growth | — | — | -75.0% | -9.5% | — |
| Dividend Yield | 1.6% | 1.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-48.7%
Start / end P/E
n/dx → n/dx
EPS bridge
11.96 → n/d
Residual
-50.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.